STOCK TITAN

Nocturne Acqu Stock Price, News & Analysis

MBTC NASDAQ

Company Description

Nocturne Acquisition Corporation (NASDAQ: MBTC) is a blank check company incorporated in the Cayman Islands with the core objective of merging, acquiring assets, or reorganizing with one or more businesses. Established on October 28, 2020, and completing its initial public offering on April 5, 2021, Nocturne is guided by experienced technology and crypto operators, aiming to leverage their industry expertise and global network to identify unique, public-ready opportunities.

The company's mission is to partner with innovative crypto or artificial intelligence (AI) technology companies, ushering in the next frontier of technological advancement. Nocturne is currently engaged in significant projects and partnerships, most notably its proposed business combination with Cognos Therapeutics, Inc., a medical technology firm focused on developing advanced devices for treating neurological diseases, including brain and spinal cancers, Alzheimer's, Parkinson's disease, epilepsy, and stroke.

On December 30, 2022, Nocturne and Cognos entered into a Merger Agreement, with the Business Combination expected to close in the fourth quarter of 2023. The combined entity will be renamed Cognos Therapeutics Holdings, Inc., trading on Nasdaq under the symbol 'COGN'. The successful completion of this merger promises to enhance Cognos' capabilities in product development and clinical trials, particularly through their SINNAISTM Implantable Smart Pump, which aims to revolutionize drug delivery for patients suffering from cancer and other neurological conditions.

The transaction is anticipated to provide Cognos with broader access to public capital markets, accelerating research and advancement of their proprietary technologies. The Nocturne team, led by CEO Henry Monzon and CFO Ka Seng (Thomas) Ao, is dedicated to supporting this transformative journey.

In recent developments, Nocturne announced the submission of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (SEC), including a preliminary proxy statement/prospectus related to the proposed Business Combination with Cognos. The filing marks a significant progress towards Cognos becoming a publicly listed company, pending shareholder approval and other customary conditions.

Nocturne's strategic focus on disruptive technologies within the blockchain/crypto and AI sectors, combined with their meticulous approach to acquisitions, positions them as a pivotal player in the evolution of technology-driven markets.

Stock Performance

$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$60.5M
Market Cap
5.2M
Shares outstanding

SEC Filings

No SEC filings available for Nocturne Acqu.

Financial Highlights

Revenue (TTM)
Net Income (TTM)
Diluted EPS (TTM)
Operating Cash Flow
Net Profit Margin
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the market cap of Nocturne Acqu (MBTC)?

The market cap of Nocturne Acqu (MBTC) is approximately 60.5M.

What is Nocturne Acquisition Corporation?

Nocturne Acquisition Corporation is a blank check company focused on merging with or acquiring businesses in the crypto and AI technology sectors.

What is the mission of Nocturne Acquisition Corporation?

Nocturne aims to partner with innovative crypto or AI tech companies to pioneer the next frontier of technological advancement.

What are the recent achievements of Nocturne?

Nocturne has entered into a Merger Agreement with Cognos Therapeutics and submitted a registration statement to the SEC, marking significant steps towards their proposed Business Combination.

What is Cognos Therapeutics?

Cognos Therapeutics is a medical technology company developing advanced devices for treating neurological diseases, including the SINNAISTM Implantable Smart Pump.

When is the Business Combination with Cognos expected to close?

The Business Combination is expected to close in the fourth quarter of 2023, subject to shareholder approval and other conditions.

What will happen to Nocturne's shares after the merger?

Post-merger, the combined company will be renamed Cognos Therapeutics Holdings, Inc., trading under the symbol 'COGN'.

Who are the key executives at Nocturne?

Henry Monzon (CEO) and Ka Seng (Thomas) Ao (CFO) are leading the company.

What industries does Nocturne focus on?

Nocturne focuses on disruptive technologies in the blockchain/crypto and artificial intelligence technology sectors.

How can shareholders participate in the upcoming merger?

Shareholders can participate by voting on the proposed Business Combination at the Extraordinary General Meeting.

Where can I find more information about the Business Combination?

Detailed information can be found in the registration statement filed with the SEC and the proxy statement/prospectus mailed to shareholders.